Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer

Phase 2TerminatedNCT00316433

Swedish Medical Center24 enrolled

Overview

The purpose of this study is to determine the safety and effectiveness of the combination of oxaliplatin and irinotecan (CPT-11) in patients with previously untreated, advanced small cell lung cancer.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Small Cell Lung Cancer

Interventions

Irinotecan (CPT-11)DRUG

Oxaliplatin (Eloxatin)DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Previously untreated extensive small cell lung cancer * No prior chemotherapy * No prior radiotherapy except for the treatment of brain metastases Exclusion Criteria: * Prior treatment for extensive stage small cell lung cancer * Known hypersensitivity to any of the components of oxaliplatin or CPT-11 * Greater than grade 2 peripheral neuropathy * Known HIV or Hepatitis B or C (active, previously treated or both)

Locations (1)

Swedish Medical Center Cancer Institute

Seattle, Washington, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.